Product Images Duloxetine

The figure shows the Kaplan-Meier estimation of the cumulative proportion of patients with relapse in a study (MDD Study 5). The x-axis represents the time from randomization to relapse in days, and the y-axis represents the proportion of patients with relapse. The graph compares the treatment of placebo and duloxetine. The treatment with duloxetine appears to show a lower proportion of patients with relapse compared to the placebo.*

The text describes a figure, specifically Figure 2, that illustrates the Kaplan-Meier estimation of the cumulative proportion of patients with relapse in a study identified as GAD Study 4. The figure displays the proportion of patients experiencing relapse over time, measured in days from randomization, for two different treatments: placebo and duloextine. The proportions are graphically presented on a vertical axis ranging from 0 to 10, with increments of 2. The horizontal axis shows the time in days from randomization to relapse, ranging from 0 to 250 with increments of 50.*

This appears to be a table showing the different dosages of duloxetine (a medication used to treat depression and anxiety) and placebo, along with the percentage of patients improved and percent improvement in pain from baseline.*

The text is a chart showing the percentage of patients with chronic lower back pain who achieved various levels of pain relief while taking a placebo or duloxetine 60 mg once daily. The chart is labelled "Figure 8" and includes data points ranging from 0 to 100 percent improvement in pain from baseline. No further information or context is available.*

The document appears to be a partial diagram or report showing the percentage of patients that improved using placebo and Duloxetine at different dosages concerning 24-hour average pain severity. Therefore, the description could be: "A report on the effectiveness of placebo and Duloxetine (60/120mg) in treating pain severity, presented by the percentage of patients who improved. The document shows a chart indicating the percentage of pain relief from baseline after taking each medication at different dosages."*

This is a package of Duloxetine Delayed-Release Capsules, USP. The package contains 10 capsules each containing 60 mg of Duloxetine hydrochloride USP equivalent to 67.3 mg of Guloxetine hydrochloride USP. It is advised to see the product insert for complete information. The storage temperature is 20° to 25° C (68" to 77" F) with excursions allowed to between 15° to 30° C (59" to 86° F). The package is not child-resistant and is intended for institutional use only. It is recommended to keep it away from children, and if dispensed for outpatient use, a child-resistant container should be used. The package also contains warnings and the NDC number. The medication guide should be given to each patient. The package is distributed by American Health Packaging, an AmerisourceBergen Company.*

This is a prescription drug called Duloxetine in the form of delayed-release capsules, each containing 30mg of the active ingredient - duloxetine hydrochloride USP. The pack has 10 capsules, and it is necessary to dispense it with a medication guide to every patient. The usual dosage is mentioned in the product insert, along with other prescribing information, precautions, and warnings. It is essential to store the drug at 20°-25°C and protect it from high temperatures. It also comes with a warning that the package is not child-resistant and should be kept out of children's reach. For outpatient use, it is suggested to use a child-resistant container. The package has a NOC number of 68180205 and is manufactured by Lupin Pharmaceuticals, distributed by American Health Packaging and Cardinal Health. Blister packaging must not be used if tampered.*